title: Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine.
abstract: OBJECTIVE
  To determine whether 3,4-diaminopyridine (3,4-DAP) would improve clinical or electrophysiologic function in patients with stable chronic demyelinating polyneuropathy.
  
  
  METHODS
  We conducted a prospective, randomized, placebo-controlled, blinded, crossover study of 3,4-DAP in 34 patients with demyelinating polyneuropathy.
  
  
  METHODS
  Of the 17 men and 17 women, who were 21 to 80 years of age, 27 had hereditary motor and sensory neuropathy type I and 7 had acquired demyelinating polyneuropathy. Treatment consisted of stepped doses of 3,4-DAP (increasing to 20 mg four times daily) or placebo for 4 days. Pretreatment and posttreatment determination of the Neurologic Disability Score (NDS); isometric muscle strength testing; median, ulnar, and peroneal nerve conduction studies; and measurement of serum 3,4-DAP were performed. Quantitative computer-assisted sensory examinations were done in five patients.
  
  
  RESULTS
  The results for the final day of treatment with 3,4-DAP or placebo and the differences between pretreatment and posttreatment findings for total NDS, sensory NDS, isometric muscle strength testing, compound muscle action potential amplitude, sensory nerve action potential amplitude, motor and sensory conduction velocities, and vibration and cold detection thresholds did not vary significantly. A small improvement of 4 points in the motor NDS (P < 0.05) was found. Five patients with electrophysiologic conduction block had no significant reduction in the degree of block.
  
  
  CONCLUSIONS
  Because no improvement was noted in most measurements of neurologic function, despite use of high doses of drug, 3,4-DAP is unlikely to be beneficial in the treatment of stable chronic demyelinating polyneuropathy.
authors.affiliation: Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Russell
authors.forename: A J
authors.initials: AJ
authors.lastname: Windebank
authors.forename: C M
authors.initials: CM
authors.lastname: Harper
mesh_terms: D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000200:Action Potentials; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077770:Amifampridine; D002607:Charcot-Marie-Tooth Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D018592:Cross-Over Studies; D003711:Demyelinating Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015221:Potassium Channels / Q000627:therapeutic use*; D011446:Prospective Studies; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology
chemical_list: D015221:Potassium Channels; D015761:4-Aminopyridine; D000077770:Amifampridine